Difference between revisions of "Talk:1217: Cells"
| Line 3: | Line 3: | ||
Sorry to correct you. Toxicity is tested for both, healthy cells an cancer cells. But as the targets for drugs are often present in both celltypes, the drug itself affect also both cells. Then you have to choose between certain death by cancer in short time and maybe death or side effects in the long row but survival. It's replacing one evil with another. Only very modern anticancer drugs (e.g. Gleevec) are selective enough to target (mostly) only cancer cells. The drawback is, as cancer in different people is not the same but different cells, you would need different drugs for everybodey affected. One way here lies in the personalized medicine, but that is very expensive... | Sorry to correct you. Toxicity is tested for both, healthy cells an cancer cells. But as the targets for drugs are often present in both celltypes, the drug itself affect also both cells. Then you have to choose between certain death by cancer in short time and maybe death or side effects in the long row but survival. It's replacing one evil with another. Only very modern anticancer drugs (e.g. Gleevec) are selective enough to target (mostly) only cancer cells. The drawback is, as cancer in different people is not the same but different cells, you would need different drugs for everybodey affected. One way here lies in the personalized medicine, but that is very expensive... | ||
[[Special:Contributions/195.37.27.58|195.37.27.58]] 10:05, 27 May 2013 (UTC)Richard | [[Special:Contributions/195.37.27.58|195.37.27.58]] 10:05, 27 May 2013 (UTC)Richard | ||
| + | |||
| + | I've seen plenty of (academic, not industry) studies where tests on healthy cells were not done. This is a fact. [[Special:Contributions/130.60.152.125|130.60.152.125]] 11:09, 27 May 2013 (UTC) | ||
Revision as of 11:10, 27 May 2013
One can test the cytotoxicity (the ability to kill cells) on a petri-dish level for cancer cells and healthy cells separately. However, this is often not done, knowingly neglecting selectivity issues one could face if the tests were done. This should be included in the explanation. The part that is written in the moment mainly explains the title text. 130.60.152.125 08:34, 27 May 2013 (UTC)
Sorry to correct you. Toxicity is tested for both, healthy cells an cancer cells. But as the targets for drugs are often present in both celltypes, the drug itself affect also both cells. Then you have to choose between certain death by cancer in short time and maybe death or side effects in the long row but survival. It's replacing one evil with another. Only very modern anticancer drugs (e.g. Gleevec) are selective enough to target (mostly) only cancer cells. The drawback is, as cancer in different people is not the same but different cells, you would need different drugs for everybodey affected. One way here lies in the personalized medicine, but that is very expensive...
195.37.27.58 10:05, 27 May 2013 (UTC)Richard
I've seen plenty of (academic, not industry) studies where tests on healthy cells were not done. This is a fact. 130.60.152.125 11:09, 27 May 2013 (UTC)
